- Home
- SPRO vs ADAG Comparison
SPRO vs ADAG Comparison
Compare SPRO & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- ADAG
- Stock Information
- Founded
- SPRO 2013
- ADAG 2011
- Country
- SPRO United States
- ADAG China
- Employees
- SPRO N/A
- ADAG N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- SPRO Health Care
- ADAG Health Care
- Exchange
- SPRO Nasdaq
- ADAG Nasdaq
- Market Cap
- SPRO 107.5M
- ADAG 90.8M
- IPO Year
- SPRO 2017
- ADAG 2021
- Fundamental
- Price
- SPRO $1.87
- ADAG $2.39
- Analyst Decision
- SPRO Buy
- ADAG Strong Buy
- Analyst Count
- SPRO 4
- ADAG 2
- Target Price
- SPRO $5.00
- ADAG $7.00
- AVG Volume (30 Days)
- SPRO 798.2K
- ADAG 105.9K
- Earning Date
- SPRO 08-12-2025
- ADAG 08-12-2025
- Dividend Yield
- SPRO N/A
- ADAG N/A
- EPS Growth
- SPRO N/A
- ADAG N/A
- EPS
- SPRO N/A
- ADAG N/A
- Revenue
- SPRO $48,576,000.00
- ADAG $103,204.00
- Revenue This Year
- SPRO N/A
- ADAG $9,789.15
- Revenue Next Year
- SPRO N/A
- ADAG $29.92
- P/E Ratio
- SPRO N/A
- ADAG N/A
- Revenue Growth
- SPRO N/A
- ADAG N/A
- 52 Week Low
- SPRO $0.51
- ADAG $1.33
- 52 Week High
- SPRO $3.22
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- SPRO 35.23
- ADAG 59.95
- Support Level
- SPRO $1.80
- ADAG $1.65
- Resistance Level
- SPRO $2.38
- ADAG $2.50
- Average True Range (ATR)
- SPRO 0.12
- ADAG 0.37
- MACD
- SPRO -0.02
- ADAG 0.03
- Stochastic Oscillator
- SPRO 12.07
- ADAG 77.89
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.